BioSpace News Archive

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it is launching a collaboration with the University of Alabama at Birmingham on the development of its single-dose, intranasal COVID-19 vaccine, named AdCOVID.

DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of pemphigus vulgaris (PV) in January 2020; anticipated delay in reporting the acute safety data from the first cohort of the DesCAARTesTM trial due to the COVID-19 pandemic

• 2019 Revenue $129 Million, Adjusted EBITDA 1 $25 Million • Q4 2019 Revenue $32 Million, Adjusted EBITDA 1 $3 Million • Year-end Cash and Equivalents of $39 million BARRIE, Ontario, March 30, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products today announced its financial results for the

Tim Armstrong, Chair of the Board of Directors of the Radiation Safety Institute of Canada, is pleased to announce two leadership changes at the Institute.

Soligenix, Inc. announced its recent accomplishments and financial results for the year ended December 31, 2019.

Correvio Pharma Corp. reported financial results for the full year ended December 31, 2019 and commented on recent accomplishments and plans.

Compass Therapeutics announced the publication of extensive data demonstrating the preclinical efficacy and safety of the company’s lead investigational therapy, CTX-471, which is currently being evaluated in a Phase 1 clinical trial.

Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit in combination with etoposide and a choice of carboplatin or cisplatin chemotherapy

Proceeds to support completion of next generation cell and gene research and manufacturing platform at ElevateBio BaseCamp and accelerate product development

Humana, a national health care company, has announced it is waiving consumer costs for treatment related to COVID-19-covered services.